AVH 2.37% $2.47 avita medical inc.

Revenue is increasing over prior year period but expenses in the...

  1. 16,292 Posts.
    lightbulb Created with Sketch. 746
    Revenue is increasing over prior year period but expenses in the last quarter were up mainly due to the costs of getting the FDA trial up and running .

    Sales in upcoming quarters should be growing as their product becomes available in more parts of the world and recell sales appear to be gaining traction.

    I believe they are still getting $1.5m in military grant money and with the existing cash and fortrend capital money they should have more than enough to get FDA approval and become cashflow positive.
 
watchlist Created with Sketch. Add AVH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.